Publication:
Experience of daratumumab in relapsed/refractory multiple myeloma: A multicenter study from Turkiye

dc.contributor.authorTekinalp, Atakan
dc.contributor.authorGedük, Ayfer
dc.contributor.authorAkdeniz, Aydan
dc.contributor.authorDemirsoy, Esra Terzi
dc.contributor.authorGürsoy, Vildan
dc.contributor.authorAk, Müzeyyen Aslaner
dc.contributor.authorBagcı, Metin
dc.contributor.authorSecilmis, Sema
dc.contributor.authorKaradağ, Fatma Keklik
dc.contributor.authorUysal, Ayşe Oruç
dc.contributor.authorDoğan, Ali
dc.contributor.authorDemircioglu, Sinan
dc.contributor.authorErol, Hasim Atakan
dc.contributor.authorAslan, Ceyda
dc.contributor.authorÖzkalemkas, Fahir
dc.contributor.authorErtop, Sehmus
dc.contributor.authorDağlı, Mehmet
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorSaydam, Guray
dc.contributor.authorMerter, Mustafa
dc.contributor.authorUral, Cihan
dc.contributor.authorCeneli, Özcan
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorÖZKALEMKAŞ, FAHİR
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.
dc.contributor.researcheridJJW-7463-2023
dc.date.accessioned2024-11-29T12:21:26Z
dc.date.available2024-11-29T12:21:26Z
dc.date.issued2023-01-01
dc.description.abstractObjective: This study aimed to evaluate patients with relapsed/ refractory multiple myeloma (RRMM) who underwent daratumumab (DARA) therapy.Materials and Methods: This multicenter retrospective study included 134 patients who underwent at least two courses of DARA from February 1, 2018, to April 15, 2022. Epidemiological, disease, and treatment characteristics of patients and treatment-related side effects were evaluated. Survival analysis was performed.Results: The median age at the start of DARA was 60 (range: 35-88), with 56 patients (41.8%) being female and 48 (58.2%) being male. The median time to initiation of DARA and the median follow-up time were 41.2 (5.1223) and 5.7 (2.1-24.1) months, respectively. The overall response rate after DARA therapy was 75 (55.9%), and very good partial response or better was observed in 48 (35.8%) patients. Overall survival (OS) and progression-free survival (PFS) for all patients were 11.6 (7.8-15.5) and 8.0 (5.1-10.9) months, respectively. OS was higher for patients undergoing treatment with DARA and bortezomib-dexamethasone (DARA-Vd) compared to those undergoing treatment with DARA and lenalidomide-dexamethasone (DARA-Rd) (16.9 vs. 8.3 months; p=0.014). Among patients undergoing DARA-Rd, PFS was higher in those without extramedullary disease compared to those with extramedullary disease (not achieved vs. 3.7 months; odds ratio: 3.4; p<0.001). The median number of prior therapies was 3 (1-8). Initiation of DARA therapy in the early period provided an advantage for OS and PFS, although it was statistically insignificant. Infusion-related reactions were observed in 18 (13.4%) patients. All reactions occurred during the first infusion and most reactions were of grade 1 or 2 (94.5%). The frequency of neutropenia and thrombocytopenia was higher in the DARA-Rd group (61.9% vs. 24.7%, p<0.001 and 42.9% vs. 15.7%, p<0.001).Conclusion: Our study provides real-life data in terms of DARA therapy for patients with RRMM and supports the early initiation of DARA therapy.
dc.identifier.doi10.4274/tjh.galenos.2023.2023.0029
dc.identifier.endpage250
dc.identifier.issn1300-7777
dc.identifier.issue4
dc.identifier.startpage242
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2023.2023.0029
dc.identifier.urihttps://hdl.handle.net/11452/48724
dc.identifier.volume40
dc.identifier.wos001162684000002
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.journalTurkish Journal Of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDexamethasone
dc.subjectBortezomib
dc.subjectMonotherapy
dc.subjectDisease
dc.subjectDaratumumab
dc.subjectRelapsed/refractory multiple myeloma
dc.subjectReal-world data
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectHematology
dc.titleExperience of daratumumab in relapsed/refractory multiple myeloma: A multicenter study from Turkiye
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication6d4676a2-f825-4560-bfa8-c7eb6daf748d
relation.isAuthorOfPublication.latestForDiscovery6d4676a2-f825-4560-bfa8-c7eb6daf748d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ozkalemkas_vd_2023.pdf
Size:
402.48 KB
Format:
Adobe Portable Document Format

Collections